Physician profile
Daniel Goldberg
NPI 1043248297
$3,988.16
in general payments reported to CMS, 2019-2025
32 companies · $13.80 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $452 · 2021: $627 · 2022: $1,500 · 2023: $479 · 2025: $13.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cue Health INC. | $866.50 | 2022 | |
| Amarin Pharma, INC. | $395.71 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $290.88 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $283.02 | 2021-2023 | Verquvo |
| Amgen INC. | $275.94 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $203.16 | 2019-2023 | |
| Inari Medical, INC. | $201.80 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.75 | 2019-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $155.58 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $150.24 | 2019-2023 | Farxiga |
| Pfizer INC. | $139.18 | 2019-2023 | |
| Novo Nordisk INC | $100.02 | 2019-2023 | Rybelsus, Ozempic |
| Lundbeck LLC | $86.14 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $71.93 | 2019 | |
| Sanofi-Aventis U.S. LLC | $64.06 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $63.45 | 2019-2020 | |
| Cvrx, INC. | $50.86 | 2022 | |
| Boston Scientific Corporation | $48.64 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $47.17 | 2021-2022 | |
| Inspire Medical Systems, INC. | $41.84 | 2023 | Inspire |
| Philips North America LLC | $36.71 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $36.20 | 2023 | Inpefa |
| Edwards Lifesciences Corporation | $25.46 | 2019 | |
| Abiomed | $24.45 | 2021 | |
| Gilead Sciences, INC. | $23.11 | 2019 | |
| Arbor Pharmaceuticals, INC. | $22.29 | 2019 | |
| Amryt Pharma Holdings Ltd | $20.20 | 2021 | |
| Daiichi Sankyo INC. | $17.46 | 2020 | |
| American Regent | $16.21 | 2023 | Injectafer |
| Ge Healthcare | $13.80 | 2025 | |
| Aegerion Pharmaceuticals, INC. | $13.25 | 2019 | |
| Esperion Therapeutics, INC. | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.